BOLT

Bolt Biotherapeutics, Inc. - Common Stock (BOLT)

About Bolt Biotherapeutics, Inc. - Common Stock (BOLT)

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Details

Daily high

$6.14

Daily low

$5.40

Price at open

$5.94

52 Week High

$10.50

52 Week Low

$4.41

Market cap

11.1M

Dividend yield

0.00%

Volume

30,768

Avg. volume

31,535

P/E ratio

-.26

Bolt Biotherapeutics, Inc. - Common Stock News